Dinaciclib - CAS# 779353-01-4 ram PARP inhibition may enhance the

PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance

Potassium otastat

InChiKey: FQTFHMSZCSUVEU-QRPNPIFTSA-N

T cell proliferation in response to ligation of the T cell receptor is inhibited by Tacrolimus

Dinaciclib - CAS# 779353-01-4 ram PARP inhibition may enhance theDinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9 activity in vitro with IC(50) values of 1, 1, 3, and 4 nmol L, respectively. Compared with flavopiridol, Dinaciclib exhibits superior activity with an improved therapeutic index. Dinaciclib induced regression of established solid tumors in a range of mouse models